A subsidiary of Tasly (600535.SH) obtained a registration certificate for injectable letitrexide

Zhitong Finance App News, Tasly (600535.SH) issued an announcement. Recently, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd. (“Jiangsu Diyi”), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for injectable letitrexide approved and issued by the State Drug Administration. The indication of the company's injectable latitrexate is that when patients are unable to receive combination chemotherapy, this product can be used as a single agent to treat advanced colorectal cancer patients unsuitable for 5-Fu/calcium folinate.